Tengion is a company at the forefront of regenerative medicine. The firm has two lead products, both of which use stem cell technology to treat diseases associated with the bladder. One product, called Neo-Bladder Augment, is targeted at patients with a birth defects and spinal cord injuries whose bladders do not function properly. The second product, called Conduit, is aimed at patients with bladder cancers. While Tengion has invested some $175 million on its products, as of 2008 the firm was running out of money and can, for the foreseeable future, only invest in one of its two lead products. The purpose of this memo is to propose which product should become Tengions lead product. Memo question: Which product should Tengion prioritize, Augment or Conduit? Your answer should draw on both qualitative factors and a quantitative analysis. For the quantitative analysis it is required that you estimate the economic value of each of Tengions lead products, Augment and Conduit and use this as part of your pricing estimate for use in market sizing. Be sure to make tables from exhibit 6a and 6b well-formatted and easy to follow tables showing your quantitative calculations